Eli Lilly and Company LLY financials

Healthcare & Pharma · Statements and segments from its SEC filings, 2007 to 2025.

Eli Lilly and Company revenue, gross and operating margin, net income, free cash flow, cash and debt by quarter and by fiscal year, and revenue by segment, read from the company's own filings with the US Securities and Exchange Commission. Free to everyone; the Risk & Quality report that scores the company is the paid step.

revenue by product: Net product revenue, Collaboration and Other Revenue, Cardiometabolic Health, Mounjaro, Zepbound, Verzenio, Trulicity, Other cardiometabolic health, Jardiance, Other oncology, Taltz, Humalog®, Other immunology, Neuroscience, Other Product, Total, Product and Service, Other, Zyprexa, Baqsimi
revenue by region: U.S., Europe, Rest of world, Japan, China

The numbers

Annual figures

Line	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$21.2B	$20B	$21.5B	$22.3B	$24.5B	$28.3B	$28.5B	$34.1B	$45B	$65.2B
Gross profit	$15.5B*	$15.5B*	$16.8B*	$17.6B*	$19.1B*	$21B*	$21.9B*	$27B*	$36.6B*	$54.1B*
Net income	$2.7B	-$204.1M	$3.2B	$8.3B	$6.2B	$5.6B	$6.2B	$5.2B	$10.6B	$20.6B
EPS (diluted)	$2.58	-$0.19	$3.13	$8.89	$6.79	$6.12	$6.90	$5.80	$11.71	$22.95
Operating cash flow	$4.9B	$5.6B	$5.5B	$4.8B	$6.5B	$7.4B	$7.6B	$4.2B	$8.8B	$16.8B
Free cash flow	$3.8B*	$4.5B*	$4.3B*	$3.8B*	$5.1B*	$6.1B*	$5.7B*	$792M*	$3.8B*	$9B*
Cash & equivalents	$4.6B	$6.5B	$7.3B	$2.3B	$3.7B	$3.8B	$2.1B	$2.8B	$3.3B	$7.3B
Total debt	$9B	$9.9B	$9.2B	$13.6B	$16.3B	$16.7B	$14.8B	$19.1B	$29.5B	$40.9B
Gross margin	73.1%	77.7%	78.2%	78.8%	77.7%	74.2%	76.8%	79.2%	81.3%	83.0%
Net margin	12.9%	-1.0%	15.0%	37.3%	25.2%	19.7%	21.9%	15.4%	23.5%	31.7%

Latest quarters

Line	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$11.4B	$13.5B*	$12.7B	$15.6B	$17.6B	$19.3B*	$19.8B	$23B
Gross profit	$9.3B*	$11.1B*	$10.5B*	$13.1B*	$14.6B*	$15.9B*	$16.2B*	$19.7B*
Net income	$970.3M	$4.4B*	$2.8B	$5.7B	$5.6B	$6.6B*	$7.4B	$7.1B
EPS (diluted)	$1.07	$4.88*	$3.06	$6.29	$6.21	$7.39*	$8.26	$7.94
Operating cash flow	$3.7B*	$2.5B*	$1.7B	$3.1B*	$8.8B*	$3.2B*	$5.3B	$10.7B*
Free cash flow	$2.4B*	$977.7M*	$156M*	$1.4B*	$6.7B*	$677.9M*	$3B*	$7.8B*
Cash & equivalents	$3.4B	$3.3B	$3.1B	$3.4B	$9.8B	$7.3B	$5.3B	$9B
Total debt	$29B	$29.5B	$34.5B	$34.2B	$40.9B	$40.9B	$39.4B	$47.9B
Gross margin	81.0%	82.2%	82.5%	84.3%	82.9%	82.5%	81.9%	85.8%
Net margin	8.5%	32.6%	21.7%	36.4%	31.7%	34.4%	37.4%	30.9%

Revenue by product

Line	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net product revenue	$22.7B	$26B	$25.5B	$28.8B	$40.7B	$61B
Collaboration and Other Revenue	$1.8B	$2.4B	$3.1B	$5.3B	$4.3B	$4.2B

Revenue by region

Line	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
U.S.	$14.2B	$16.8B	$18.2B	$21.8B	$30.4B	$43.5B
Europe	$4.2B	$4.8B	$4.3B	$6.2B	$6.9B	$11.6B
Rest of world	$2.4B	$2.7B	$2.9B	$2.9B	$4.3B	$6.1B
Japan	$2.6B	$2.4B	$1.7B	$1.7B	$1.8B	$2.1B
China	$1.1B	$1.7B	$1.5B	$1.5B	$1.7B	$2B

* derived: a fourth quarter as the year less the three filed quarters, or a remainder as the total less the parts. All other figures are as filed.

About this page

Every figure on this page is read from Eli Lilly and Company's own SEC filings: the statement lines from the SEC's XBRL company-facts feed, the revenue splits from the segment and revenue notes of each 10-K and 10-Q. Nothing is typed in or estimated. The cache refreshes daily.

Read the Risk & Quality report on Eli Lilly and Company or see all companies.